LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

MannKind Corp

Closed

SectorHealthcare

5.5 -1.26

Overview

Share price change

24h

Current

Min

5.48

Max

5.69

Key metrics

By Trading Economics

Income

-12M

668K

Sales

-1.8M

77M

P/E

Sector Avg

41.727

35.733

Profit margin

0.873

Employees

403

EBITDA

-17M

9.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+84.74% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

217M

1.4B

Previous open

6.76

Previous close

5.5

News Sentiment

By Acuity

50%

50%

156 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

MannKind Corp Chart

Past performance is not a reliable indicator of future results.

Related News

9 Sept 2025, 23:37 UTC

Hot Stocks

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 Sept 2025, 20:41 UTC

Earnings

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 Sept 2025, 20:30 UTC

Earnings

GameStop 2Q Sales, Profit Rise

9 Sept 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 Sept 2025, 21:35 UTC

Earnings

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 21:32 UTC

Earnings

Oracle's Backlog Swells With Big Customer Deals -- Update

9 Sept 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Sept 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 Sept 2025, 20:26 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:23 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:12 UTC

Earnings

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 Sept 2025, 20:07 UTC

Earnings

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Software Revenue $5.72B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Synopsys 3Q Adj EPS $3.39 >SNPS

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Rev $14.93B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q EPS $1.01 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Synopsys 3Q EPS $1.50 >SNPS

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Services Revenue $1.35B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Adj EPS $1.47 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

84.74% upside

12 Months Forecast

Average 10.29 USD  84.74%

High 15 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

156 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
help-icon Live chat